Lundbeck’s Bocunebart Shows Positive Results in Phase IIb Migraine Trial

A New Step Forward in Migraine Treatment
Migraine is not just a normal headache. For many people, it affects work, sleep, family life, and daily activities. Even with many migraine medicines available today, a large number of patients still do not get proper relief.
Now, Lundbeck has shared positive results from its Phase IIb PROCEED clinical trial for bocunebart, an investigational monoclonal antibody being studied for migraine prevention. The results were presented during the American Headache Society Congress held in Orlando, Florida from June 4–7, 2026.
The study results are important because they show that bocunebart may become a new treatment option for people who have already failed several preventive migraine therapies.
What Is Bocunebart?
Bocunebart, also known as Lu AG09222, is an investigational monoclonal antibody developed by Lundbeck. The treatment targets PACAP, which stands for pituitary adenylate cyclase-activating polypeptide.
PACAP is a neuropeptide linked to migraine attacks. Unlike current anti-CGRP migraine treatments, bocunebart works through a different biological pathway. This makes it a potentially useful option for patients who do not respond well to existing migraine medicines.
The drug is still under investigation and has not yet been approved by any regulatory authority.
Understanding the PROCEED Trial
The PROCEED trial was a Phase IIb clinical study designed to evaluate the efficacy, safety, and tolerability of bocunebart.
The trial studied both subcutaneous and intravenous dosing methods. However, after an interim analysis, the subcutaneous part was stopped because it did not meet expectations. The study then continued with the intravenous dosing approach.
A total of 429 patients across 14 countries participated in the intravenous part of the trial. These patients had previously failed one to four preventive migraine treatments within the last 10 years.
The main goal of the study was to measure the reduction in monthly migraine days over a 12-week period.
Bocunebart Met the Primary Endpoint
The intravenous part of the PROCEED trial successfully met its primary endpoint.
Patients treated with bocunebart experienced a statistically significant reduction in monthly migraine days compared with placebo during Weeks 1 to 12.
Patients receiving bocunebart showed an average reduction of 4.24 monthly migraine days. In comparison, placebo-treated patients experienced a reduction of 2.86 days.
The treatment difference between bocunebart and placebo was 1.38 days, with a p-value of 0.0178, showing statistical significance.
Stronger Results in Chronic Migraine Patients
The trial results were even more impressive in patients with severe chronic migraine.
When pooled Phase II data were analyzed, patients treated with bocunebart experienced a reduction of 5.94 monthly migraine days compared with 3.63 days in the placebo group.
This resulted in a treatment difference of 2.31 days with a highly significant p-value below 0.001.
These findings suggest that bocunebart may provide greater benefits for patients living with chronic and difficult-to-treat migraine conditions.
Safety and Tolerability Findings
According to Lundbeck, bocunebart was generally well tolerated throughout the study.
Researchers reported no new safety concerns during the treatment period. The most common side effect observed was nasopharyngitis, which was reported in at least 5% of patients.
Additional Phase I clinical data also showed positive safety findings when bocunebart was used together with ubrogepant, a commonly prescribed acute migraine medicine.
Previous studies had already shown encouraging safety results when bocunebart was used alongside triptans.
Together, these findings strengthen confidence in the safety profile of the treatment.
Expert Opinions on the Trial Results
Dr. Jessica Ailani, the coordinating investigator of the PROCEED trial and a certified headache specialist based in Washington DC, expressed optimism about the study findings.
According to Dr. Ailani, many migraine patients still struggle with poor disease control despite advances in available therapies. She stated that the clinical evidence seen so far highlights the potential of bocunebart as a promising new migraine prevention therapy.
Johan Luthman, Executive Vice President and Head of Research and Development at Lundbeck, also described the results as an important milestone for migraine research.
He explained that the findings strengthen confidence in targeting the PACAP pathway and support continued clinical development of bocunebart.
About the HOPE Trial
Before the PROCEED study, Lundbeck also conducted the HOPE Phase IIa migraine trial.
The HOPE study evaluated the safety and efficacy of a single intravenous infusion of bocunebart in migraine patients who had failed previous preventive treatments.
The study included 237 patients and compared two doses of bocunebart against placebo.
The trial focused on changes in monthly migraine days over a four-week period and helped provide early evidence supporting the PACAP inhibition approach.
Why PACAP Is Important in Migraine Research
Most modern migraine therapies focus on the CGRP pathway. Bocunebart is different because it targets PACAP, another important biological pathway linked to migraine attacks.
This creates a completely new treatment approach that could help patients who do not respond to current anti-CGRP therapies.
Researchers believe PACAP inhibition could become a major advancement in future migraine prevention strategies.
The Global Burden of Migraine
Migraine remains one of the most common neurological diseases worldwide.
It is currently one of the leading causes of disability, especially in people under 50 years old. Migraine attacks often come with nausea, vomiting, and sensitivity to light and sound.
As the disease becomes more severe, patients may experience chronic migraine, which can significantly reduce quality of life and productivity.
Because of this, there is still a major need for new and more effective preventive treatments.
What Happens Next?
Following the positive PROCEED results, Lundbeck is now preparing for further clinical development of bocunebart for migraine prevention.
The company also hosted a webcast and conference call for investors and analysts to discuss the latest findings and future plans for the program.
Although bocunebart is still investigational, the current data provide strong support for continued development.
Final Thoughts
The Phase IIb PROCEED trial marks an important development in migraine research. Bocunebart demonstrated meaningful reductions in monthly migraine days, especially in patients with chronic migraine who had already failed previous preventive therapies.
Its unique PACAP-targeting mechanism also offers a fresh treatment approach beyond existing anti-CGRP therapies.
While more research is still needed before approval, the results presented by Lundbeck suggest that bocunebart could become a valuable future option for patients struggling with difficult-to-treat migraine.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!